A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs BLU-5937 (Primary)
- Indications Cough
- Focus Proof of concept; Therapeutic Use
- Acronyms RELIEF
- Sponsors BELLUS Health
- 18 Nov 2019 Planned number of patients changed from 65 to 68.
- 08 Aug 2019 According to an BELLUS Health media release, the company expects to complete enrollment in this study in the first quarter of 2020.
- 30 Jul 2019 According to a BELLUS Health media release, the first patient has been enrolled in this study.